Australian Entrepreneur Discloses Complete Process of Using AI to Design mRNA Cancer Vaccines for Pets, Involving 300GB of Genetic Data and Multi-Model Collaboration

Odaily News Australian AI consulting firm founder Paul Conyngham posted on the X platform, disclosing the complete technical process of using multiple AI chatbots to design a personalized mRNA cancer vaccine for his pet dog. The dog was diagnosed with malignant mast cell cancer in May 2024. Subsequently, approximately 300GB of data was obtained through whole-genome and RNA sequencing. With the collaborative efforts of ChatGPT, Gemini, and Grok, target screening, protein structure modeling, and vaccine sequence design were completed. Ultimately, a c-KIT gene mutation was identified and 7 neoantigen targets were screened.

The vaccine was prepared by a relevant research team at the University of New South Wales and administered at the University of Queensland's School of Veterinary Science. The overall treatment plan included the combined application of an mRNA vaccine, a tyrosine kinase inhibitor, and a PD-1 inhibitor, with the dosing schedule assisted by AI planning. After treatment began in December 2025, some tumors showed shrinkage within three months, but there were still non-responsive lesions requiring surgical intervention. Experts pointed out that this case is a single individual practice and does not yet constitute a universal medical conclusion.